155 related articles for article (PubMed ID: 36425867)
1. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial.
Fujisawa T; Tsuchiya T; Kato M; Mizuide M; Takakura K; Nishimura M; Kutsumi H; Matsuda Y; Arai T; Ryozawa S; Itoi T; Isayama H; Saya H; Yahagi N
EClinicalMedicine; 2023 Jan; 55():101731. PubMed ID: 36425867
[TBL] [Abstract][Full Text] [Related]
2. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer.
Nishimura M; Matsukawa M; Fujii Y; Matsuda Y; Arai T; Ochiai Y; Itoi T; Yahagi N
Gastrointest Endosc; 2018 Apr; 87(4):1126-1131. PubMed ID: 29122598
[TBL] [Abstract][Full Text] [Related]
3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis.
Matsuda Y; Fujii Y; Matsukawa M; Ishiwata T; Nishimura M; Arai T
Oncol Lett; 2019 Oct; 18(4):4100-4105. PubMed ID: 31516610
[TBL] [Abstract][Full Text] [Related]
5. Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer.
Ye J; Suizu F; Yamakawa K; Mukai Y; Yoneyama H; Kondo J; Kato M; Nishiyama A; Yahagi N; Kadota K
Mol Ther Oncol; 2024 Jun; 32(2):200812. PubMed ID: 38799652
[TBL] [Abstract][Full Text] [Related]
6. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.
Suzuki K; Yokoyama J; Kawauchi Y; Honda Y; Sato H; Aoyagi Y; Terai S; Okazaki K; Suzuki Y; Sameshima Y; Fukushima T; Sugahara K; Atreya R; Neurath MF; Watanabe K; Yoneyama H; Asakura H
J Crohns Colitis; 2017 Feb; 11(2):221-228. PubMed ID: 27484097
[TBL] [Abstract][Full Text] [Related]
8. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
10. Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.
Ye J; Suizu F; Yamakawa K; Mukai Y; Kato M; Yoneyama H; Yahagi N; Matsuda Y
Eur J Immunol; 2023 Sep; 53(9):e2250160. PubMed ID: 37248998
[TBL] [Abstract][Full Text] [Related]
11. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
12. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
13. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
15. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
[TBL] [Abstract][Full Text] [Related]
16. Results of a single-arm pilot study of
Ross PJ; Wasan HS; Croagh D; Nikfarjam M; Nguyen N; Aghmesheh M; Nagrial AM; Bartholomeusz D; Hendlisz A; Ajithkumar T; Iwuji C; Wilson NE; Turner DM; James DC; Young E; Harris MT
ESMO Open; 2022 Feb; 7(1):100356. PubMed ID: 34953400
[TBL] [Abstract][Full Text] [Related]
17. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
[TBL] [Abstract][Full Text] [Related]
18. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
20. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C; Frontado Graffe FJ; Bartels A; Sadeghlar F; Zhou T; Mahn R; Marinova M; Feldmann G; Brossart P; Glowka TR; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Gastrointest Oncol; 2023 Feb; 14(1):352-365. PubMed ID: 36915455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
